Drug Database
FE

fentanyl citrate (OX20 / Rapinyl / EN 3267)

✓ Approved

Kyowa Kirin Co., Ltd. · 小分子 · 小分子

什么是 fentanyl citrate?

fentanyl citrate 是一种小分子,由Kyowa Kirin Co., Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)、Sublingual (SL)/Oral Transmucosal、Topical。

药物档案

商品名OX20, Rapinyl, EN 3267
公司Kyowa Kirin Co., Ltd.
药物类别小分子
给药途径Oral (PO), Sublingual (SL)/Oral Transmucosal, Topical
状态Approved

治疗适应症

fentanyl citrate 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Cancer pain✓ Approved

相关研究文献

PubMedAJE advances : research in epidemiology2026-11-19

Monitoring longitudinal public interest in opioid risk and response fentanyl vs. Narcan vs. naloxone: public search patterns.

Sheu Angel A, Bourmand Raika R, DiFiore Emma E

The opioid crisis in the United States has evolved rapidly over the last decade, with fentanyl-a potent synthetic opioid-playing a central role in the rising overdose death toll. Naloxone (brand name Narcan), an opioid antagonist, has become a cornerstone of harm-reduction strategies due to its effectiveness in reversing overdoses. Although public health initiatives to promote fentanyl and naloxone use have increased, there is limited understanding of how public interest in these substances has evolved, especially in relation to overdose events. This study utilizes Google Trends to assess longitudinal public interest in "fentanyl" "Narcan" and "naloxone" from January 1, 2015, to January 1, 2025. Relative search volumes (RSVs) were extracted monthly, normalized on a 0-100 scale, and plotted. Peaks in RSV were contextualized through qualitative analysis of media coverage, Centers for Disease Control and Prevention announcements, public health policies, and notable overdose-related events. Geographic distribution of searches was also examined by state. "Fentanyl" had the highest RSV consistently, with an average monthly RSV of 32, compared to 9 for "Narcan" and 5 for "naloxone." All 3 terms displayed upward trends, though "fentanyl" interest increased the most significantly. Key spikes in search volume were linked to high-profile events, including the US Food and Drug Administration's over-the-counter approval of Narcan in 2023 and mass fentanyl overdose incidents in 2016, 2018, and 2022. Geographic trends revealed fentanyl-dominant interest in Southwestern states, while Eastern states had a higher interest in "Narcan" and "naloxone." This study identifies a significant and consistent disparity in public interest between fentanyl and opioid overdose reversal agents, suggesting an opportunity for overdose prevention education. Public health strategies can utilize this insight to design targeted campaigns that raise awareness of naloxone access, and training can better tailor their instructional programs. Google Trends proves to be a valuable tool for monitoring public awareness and guiding data-driven responses to public health crises.

PMID 43053799
阅读全文 →
PubMedCancer & metabolism2026-11-19

Salidroside decreases lipid abundance, mitochondrial function, and expression of the mitochondrial citrate transporter SLC25A1 via miR-1343-3p in gastric cancer.

Cao Mingyuan M, Zhang Zhendong Z, Du Yuxin Y, Fang Jin J et al.

To investigate the potential mechanisms by which salidroside regulates mitochondrial function, SLC25A1 expression, and lipid abundance in gastric cancer (GC) cells via miR-1343-3p. Transcriptome sequencing was performed on MGC-803 cells before and after salidroside treatment to identify differentially expressed miRNAs and mRNAs. Bioinformatic analysis was then used to screen for candidate molecules. The interaction between miR-1343-3p and SLC25A1 was validated by dual-luciferase reporter assay, sequence alignment, and RNA immunoprecipitation (RIP). Mitochondrial morphology and function were examined by transmission electron microscopy and fluorescent probes. MGC-803 and AGS cells were used to assess the effects of salidroside, miR-1343-3p modulation, and SLC25A1 silencing on mitochondrial citrate export, lipid abundance, and cell proliferation. Furthermore, a nude mouse xenograft model was established to evaluate the effects of salidroside and a miR-1343-3p agomir on tumor growth, the expression of miR-1343-3p and SLC25A1, and tumor metabolic status. Transcriptome sequencing revealed 44 differentially expressed miRNAs and 1,384 differentially expressed mRNAs in MGC-803 cells following salidroside treatment. Among them, miR-1343-3p was significantly upregulated as a tumor-suppressive miRNA, while SLC25A1, a mitochondrial citrate transporter, was significantly downregulated. RT-qPCR and Western blot results demonstrated that salidroside significantly increased the expression of miR-1343-3p while decreasing the mRNA and protein expression of SLC25A1. Dual-luciferase reporter, sequence alignment, and RIP assays confirmed that miR-1343-3p directly targets SLC25A1. Further studies showed that salidroside treatment, miR-1343-3p overexpression, and SLC25A1 silencing could all cause the accumulation of mitochondrial citrate, reduced mitochondrial membrane potential, increased ROS production, and decreased the levels of NADH, ATP, acetyl-CoA, free fatty acids, cholesterol, and triglycerides, while significantly inhibiting GC cell proliferation. However, after knocking down miR-1343-3p, the opposite results were observed, which were efficiently rescued by salidroside. In vivo, both salidroside treatment and the miR-1343-3p agomir administration significantly reduced tumor volume and weight. Tumor tissues from these groups showed increased miR-1343-3p expression, decreased SLC25A1 expression, and lipid metabolic changes consistent with those observed in vitro. Salidroside inhibits GC cell proliferation and tumor growth by upregulating the tumor-suppressive miR-1343-3p, which directly targets and downregulates the mitochondrial citrate transporter SLC25A1. Meanwhile, decreased mitochondrial citrate export, impaired mitochondrial function, and reduced lipid abundance are observed. These findings indicate that miR-1343-3p and SLC25A1 may be promising therapeutic targets for metabolic intervention in gastric cancer.

PMID 43053216
阅读全文 →
PubMedNeurocase2026-11-19

Characteristic basal ganglia injury in fentanyl- and cocaine-related hypoxic brain injury: a case report.

Yellin Emma E, Arnsten Amy A, Vives-Rodriguez Ana A, Fesharaki-Zadeh Arman A

We present the case of a 33-year-old woman who developed bilateral basal ganglia injury following a hypoxic brain injury in the setting of fentanyl and cocaine use. Notably, she never required intubation and received only minimal supplemental oxygen, yet MRI demonstrated bilateral basal ganglia diffusion restriction on diffusion-weighted imaging (DWI) with corresponding T2/FLAIR hyperintensities, findings most associated with significant ischemic injury. Rather than the movement disorders typically seen with basal ganglia lesions, her predominant presentation was neuropsychiatric, characterized by apathy, impulsivity, and risk-taking behavior. Drawing on the mechanistic overlap with traumatic brain injury affecting Prefrontal cortical (PFC) and subcortical networks, she was treated with a novel combination of guanfacine, bupropion, and N-acetylcysteine (NAC), targeting executive dysfunction, apathy, and neuroinflammatory pathways, respectively. This case highlights a rare neuropsychiatric presentation of drug-related hypoxic basal ganglia injury and provides a framework for understanding and treating the behavioral sequelae of such injury. It also adds to a small but growing body of literature linking opioid overdose to characteristic basal ganglia diffusion restriction, even in the absence of overt hypoxia.

PMID 43053706
阅读全文 →
PubMedAsian journal of anesthesiology2026-11-19

Comparative Study Between Analgesic Effects of Quadratus Lumborum Block (QLB) and Intravenous Analgesia in Patients Undergoing Nephrectomy.

Bodavula Venkata Naga Siva Sai Sandeep VNSSS, Chinthalapudi Mounika M, K Ragha Deepti RD

Nephrectomy is associated with significant postoperative pain due to surgical trauma and visceral manipulation. Intravenous opioids are commonly used for analgesia but may cause systemic adverse effects. This study compared postoperative analgesic outcomes between quadratus lumborum block (QLB) and conventional intravenous analgesia (IVA) in patients undergoing nephrectomy. This hospital-based observational study included 60 patients, with 30 patients in each group. Group I received QLB with 0.25% bupivacaine, while Group II received conventional IVA. Postoperative pain was assessed using the visual analogue scale (VAS) every two hours for 24 hours. Sedation was evaluated using the Modified Ramsay Sedation Score. Hemodynamic parameters, intraoperative fentanyl use, and postoperative tramadol and paracetamol consumption were recorded. Data were analyzed using SPSS v26.0. Intergroup comparisons were performed using independent t-tests. VAS scores were significantly lower in the QLB group during the first 8 postoperative hours ( P < 0.001). Intraoperative fentanyl (100.00 µg vs. 161.67 µg), postoperative tramadol (61.67 mg vs. 148.33 mg), and paracetamol consumption (2.23 g vs. 3.27 g) were lower in the QLB group. Time to first rescue analgesia was longer in the QLB group (4.52 hours vs. 0.43 hours; P = 0.001). Sedation scores were lower during the first 4 hours. Intraoperative hemodynamic parameters also differed between groups, although baseline mean arterial pressure was significantly lower in the QLB group. QLB was associated with lower early postoperative pain scores, reduced analgesic requirements, and longer time to first rescue analgesia compared with IVA. The observational design limits causal interpretation of these findings.

PMID 43053653
阅读全文 →
PubMedHarm reduction journal2026-11-19

Multi-stakeholder perspectives on acceptability and delivery of buprenorphine for women who use drugs.

Austin Elizabeth J EJ, Violette Lauren R LR, Stewart Jenell J, Glick Sara N SN et al.

Women who use drugs (WWUD) face substantial barriers to accessing medications for opioid use disorder (MOUD), including buprenorphine. As part of a formative evaluation to co-design a community-based intervention for MOUD delivery, we explored multi-stakeholder perspectives on the acceptability and delivery of buprenorphine for WWUD. We conducted qualitative interviews with 16 WWUD (who reported lifetime history of injection drug use) and 5 healthcare and harm reduction professionals (HHRP) who work closely with WWUD. Interviews asked open-ended questions about attitudes and beliefs towards buprenorphine, experience receiving (WWUD) or facilitating receipt (HHRP) of buprenorphine, and barriers to using buprenorphine in the future. Interviews were audio-recorded, professionally-transcribed, and coded using Rapid Assessment Process. Two coders generated templated coding summaries of each transcript, which were placed into a matrix and iteratively reviewed to identify cross-cutting themes. Qualitative learnings were finalized with the investigative team and confirmed with community advisors. Among 16 WWUD participants, 12 (75%) identified as White and 11 (69%) were unstably housed. All participants had a lifetime history of injection drug use and 10 (63%) had ever tried buprenorphine. Most WWUD did not perceive buprenorphine to be the right choice for them, in part due to beliefs about its limited effectiveness and concerns about their personal safety and stigmatizing beliefs. Fear of physical discomfort from buprenorphine inductions further discouraged willingness, especially for those using fentanyl. Participants described the ways in which housing instability and limited social supports compounded barriers to starting and staying on buprenorphine, but that harm reduction approaches might help. WWUD face multilevel barriers to buprenorphine use and both WWUD and HHRP are working to respond to the ways in which fentanyl further heightens those barriers. Future efforts to expand buprenorphine use among WWUD should consider supports that improve the ease and acceptability of buprenorphine delivery.

PMID 43053082
阅读全文 →
PubMedDrug testing and analysis2026-11-19

Emerging Trends in Etomidate and Xylazine: Wastewater-Based Monitoring Reveals the First Detection of Etomidate in Australia.

Peake Brock B, Barber Emma E, Keller Emma L EL, Simpson Bradley S BS et al.

The emergence of non-opioid adulterants in illicit opioid products has increased the complexity and health risks associated with illicit drug markets worldwide. Although xylazine has become a recognised adulterant within illicit opioid markets, etomidate has emerged as a novel adulterant in the fentanyl supply and illicit electronic cigarette (vape) products. Wastewater-based epidemiology provides a population-level surveillance approach capable of detecting emerging psychoactive substances before they are recognised through conventional monitoring systems. This study reports the first detection of etomidate in Australian wastewater and examines temporal and spatial trends in etomidate and xylazine over a one-year period. A total of 936 influent wastewater samples were analysed across seven collection periods between April 2025 and April 2026 from metropolitan and regional catchments throughout Australia. Xylazine was detected in 188 samples and etomidate in 183 samples. Xylazine was widely distributed across Australia but declined steadily throughout the study, with detection frequency decreasing from 41% to 5%. In contrast, etomidate detections increased from 28% to 43% across major cities and expanded into regional areas during the latter stages of monitoring. These wastewater findings provided early evidence of etomidate's emergence in Australia, preceding subsequent reports through other surveillance systems. The contrasting trends are consistent with international reports describing a shift from xylazine towards alternative veterinary sedatives, including etomidate and the emergence of etomidate in electronic cigarettes. These findings demonstrate the value of national wastewater surveillance programs for monitoring changes in illicit drug markets and informing timely public health and harm reduction responses.

PMID 43053574
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多fentanyl citrate